Influenza vaccine
The influenza vaccine elicits protective immunity against influenza virus, chiefly by generating antibodies against the surface glycoprotein hemagglutinin (HA), which the virus uses to bind host cells; neuraminidase contributes as a secondary target.
The influenza vaccine elicits protective immunity against influenza virus, chiefly by generating antibodies against the surface glycoprotein hemagglutinin (HA), which the virus uses to bind host cells; neuraminidase contributes as a secondary target. Formulations differ by population and platform: standard-dose inactivated vaccines, high-dose or adjuvanted versions for older adults whose responses are weaker, live-attenuated vaccine given intranasally, and recombinant protein vaccines produced without eggs. Children aged 6–35 months receive a reduced dose (0.25 mL, 7.5 μg HA per strain) while older children and adults receive the full amount.
Annual reformulation is forced by the virus rather than chosen. Point mutations accumulate in the antibody-binding sites of HA — antigenic drift — so last season's antibodies bind this season's virus less well, and strain selection must be made months ahead of the season, with mismatch a recurring cause of low effectiveness. Effectiveness is therefore variable, typically moderate and lower in years of poor match or in older adults, and egg-based manufacture adds its own problem, since adaptation of the seed virus to grow in eggs can itself alter the antigenic surface. Reassortment between influenza A viruses of different hosts — antigenic shift — produces the abrupt novel subtypes behind pandemics, against which seasonal vaccines offer little.
vaccination matters most for those least able to withstand infection: older adults, young infants, pregnant women, and immunocompromised people, including those on immunosuppressive targeted therapies such as rituximab, which depletes the B cells the vaccine depends on. Patients receiving immune checkpoint inhibitors are also a group of interest, though these agents enhance rather than suppress immune responses. No vaccine is approved below six months of age, leaving maternal immunization as the means of protecting the youngest infants. That gap, together with the yearly reformulation cycle and the short duration of protection, motivates work toward universal vaccines — HA stem-targeting nanoparticle designs and adjuvanted platforms aimed at the conserved regions that drift cannot easily change.
Where the papers sit
25 papers from the last 6 months study influenza vaccine directly · updated from PubMed 14 Nov 2026
Study type 0 clinical trials · 9 observational · 12 human data · 2 preclinical · 2 unclassified
Themes one subject · 2 new directions
Those 25 are all about one subject.
-
Seasonal Influenza Prevention
Seasonal influenza prevention spans real-world vaccine effectiveness, safety, uptake, and program value across ages and settings. Test-negative studies assess protection against medical visits, hospitalization, and death, while recombinant and standard-dose products are compared economically. Communication, trust, behavioral drivers, and gaps between willingness and uptake remain central barriers. Immune-response studies probe T-cell memory and vaccine-associated outcomes, but no single strategy unifies the field.
Seasonal influenza vaccination programs become infrastructure for pandemic preparedness
Seasonal influenza vaccination programs in low- and middle-income countries were found to do more than prevent influenza: they provided a maintained operational “warm base” that enabled faster, higher-coverage COVID-19 mass vaccination, although some systems required modification for pandemic speed and volume. This changes the role assigned to influenza vaccination from a disease-specific intervention to an investment in emergency vaccination readiness. 42691820Sep
Influenza vaccination is associated with survival during immune checkpoint inhibitor therapy
Immune checkpoint inhibitor therapy in cancer was studied alongside the assumption that any vaccine-related survival advantage might be specific to SARS-CoV-2 mRNA vaccination, but the paper found similar lower-mortality associations for influenza, adenoviral COVID-19, and mRNA COVID-19 vaccines. Influenza vaccination therefore becomes a population-level comparator suggesting a broader vaccine-associated interaction with cancer treatment rather than an mRNA-specific tumor-sensitization mechanism. 42673464Aug
Papers
The 25 papers from the last 6 months that study influenza vaccine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Seasonal Influenza Prevention (25)
- Asymmetric cell division is predictive of human T cell vaccine responses. Science advances · 11 Nov 2026 PMID 43013659
- Cost-effectiveness of recombinant influenza vaccine compared with standard-dose influenza vaccine among adults 50 years of age and older in Hong Kong. Human vaccines & immunotherapeutics · 2 Nov 2026 PMID 42969388
- Frontline Staff Vaccine Communication During Pediatric Well-Child Encounters: A Mixed-Methods Study. Pediatrics · 23 Oct 2026 PMID 42914140
- Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026. Infection · 9 Oct 2026 PMID 42853491
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study. Journal of global health · 9 Oct 2026 PMID 42852605
- Validation of the behavioural and social drivers of influenza vaccine survey in Australia: Cognitive interviews and psychometric evaluation. Human vaccines & immunotherapeutics · 4 Oct 2026 PMID 42829802
- Influenza vaccine effectiveness against influenza-related medical visits, hospitalization and death among adults aged 65 years and older in Taiwan: interim 2024-2025 season result using standard-dose inactivated influenza vaccine. Vaccine · 29 Sept 2026 PMID 42810173
- Trust in government institutions and influenza vaccine acceptance among U.S. adults. Vaccine · 29 Sept 2026 PMID 42810171
- Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study. The Lancet regional health. Southeast Asia · 17 Sept 2026 PMID 42751285
- Fibre-enhanced fluorescent-based immunosorbent assay. Methods and applications in fluorescence · 9 Sept 2026 PMID 42716089
- Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study. Vaccine · 6 Sept 2026 PMID 42702143
- Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort. Vaccine · 6 Sept 2026 PMID 42702142
- Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada. Vaccine · 3 Sept 2026 PMID 42691825
- Investments in seasonal influenza vaccination programs pack a punch for pandemic preparedness. Vaccine · 3 Sept 2026 PMID 42691820
- Monocyte-derived galectin-1hi cells provide innate immune help in the generation of functional memory CD8+ T cells. Nature immunology · 31 Aug 2026 PMID 42675114
- Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy. Proceedings of the National Academy of Sciences of the United States of America · 31 Aug 2026 PMID 42673464
- Factors associated with influenza vaccine uptake among healthcare workers in Georgia, 2021-2024. PloS one · 25 Aug 2026 PMID 42640914
- Factors associated with influenza vaccine uptake and intention among public transportation drivers: A cross-sectional study from Lebanon. Human vaccines & immunotherapeutics · 24 Aug 2026 PMID 42636327
- Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066
- Temporal shifts in public perceptions of influenza and its vaccine before, during, and after COVID-19 in a fragile nation. Annals of medicine · 20 Aug 2026 PMID 42621836
- Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases. Journal of infection and public health · 3 Jul 2026 PMID 42398453
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
- Influenza, pneumococcal, and herpes zoster vaccination in Italy: Knowledge, uptake, and determinants across the adult life course. Vaccine · 20 Jun 2026 PMID 42322680
- Up to Date Status and Acceptance of the Influenza Vaccine among a National Sample of Emergency Department Patients. The Journal of emergency medicine · 15 Jun 2026 PMID 42296645
- Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study. Vaccine · 12 Jun 2026 PMID 42284809
By study type
Observational studies and case reports (9)
- Influenza vaccine protection and contact patterns among outpatients with influenza-like illness during the 2024-2025 season in China: a test-negative case-control study. Journal of global health · 9 Oct 2026 PMID 42852605
- Influenza vaccine effectiveness against influenza-related medical visits, hospitalization and death among adults aged 65 years and older in Taiwan: interim 2024-2025 season result using standard-dose inactivated influenza vaccine. Vaccine · 29 Sept 2026 PMID 42810173
- Trust in government institutions and influenza vaccine acceptance among U.S. adults. Vaccine · 29 Sept 2026 PMID 42810171
- Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort. Vaccine · 6 Sept 2026 PMID 42702142
- Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada. Vaccine · 3 Sept 2026 PMID 42691825
- Factors associated with influenza vaccine uptake among healthcare workers in Georgia, 2021-2024. PloS one · 25 Aug 2026 PMID 42640914
- Factors associated with influenza vaccine uptake and intention among public transportation drivers: A cross-sectional study from Lebanon. Human vaccines & immunotherapeutics · 24 Aug 2026 PMID 42636327
- Association between COVID-19 booster vaccination and influenza mortality: a nationwide retrospective cohort study using the SIVEP-Gripe database in Brazil. Immunologic research · 21 Jun 2026 PMID 42324378
- Up to Date Status and Acceptance of the Influenza Vaccine among a National Sample of Emergency Department Patients. The Journal of emergency medicine · 15 Jun 2026 PMID 42296645
Human data, design not indexed (12)
- Asymmetric cell division is predictive of human T cell vaccine responses. Science advances · 11 Nov 2026 PMID 43013659
- Cost-effectiveness of recombinant influenza vaccine compared with standard-dose influenza vaccine among adults 50 years of age and older in Hong Kong. Human vaccines & immunotherapeutics · 2 Nov 2026 PMID 42969388
- Frontline Staff Vaccine Communication During Pediatric Well-Child Encounters: A Mixed-Methods Study. Pediatrics · 23 Oct 2026 PMID 42914140
- Validation of the behavioural and social drivers of influenza vaccine survey in Australia: Cognitive interviews and psychometric evaluation. Human vaccines & immunotherapeutics · 4 Oct 2026 PMID 42829802
- Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study. Vaccine · 6 Sept 2026 PMID 42702143
- Investments in seasonal influenza vaccination programs pack a punch for pandemic preparedness. Vaccine · 3 Sept 2026 PMID 42691820
- Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy. Proceedings of the National Academy of Sciences of the United States of America · 31 Aug 2026 PMID 42673464
- Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066
- Temporal shifts in public perceptions of influenza and its vaccine before, during, and after COVID-19 in a fragile nation. Annals of medicine · 20 Aug 2026 PMID 42621836
- Influenza and herpes zoster vaccine effectiveness in autoimmune or immune-mediated diseases. Journal of infection and public health · 3 Jul 2026 PMID 42398453
- Influenza, pneumococcal, and herpes zoster vaccination in Italy: Knowledge, uptake, and determinants across the adult life course. Vaccine · 20 Jun 2026 PMID 42322680
- Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study. Vaccine · 12 Jun 2026 PMID 42284809
Preclinical: animal, cell and lab studies (2)
- Fibre-enhanced fluorescent-based immunosorbent assay. Methods and applications in fluorescence · 9 Sept 2026 PMID 42716089
- Monocyte-derived galectin-1hi cells provide innate immune help in the generation of functional memory CD8+ T cells. Nature immunology · 31 Aug 2026 PMID 42675114
Unclassified: not yet indexed with MeSH (2)
- Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026. Infection · 9 Oct 2026 PMID 42853491
- Effectiveness of a trivalent inactivated split-virion influenza vaccine (Tri Fluvac) in Thailand: a phase IV test-negative case-control study. The Lancet regional health. Southeast Asia · 17 Sept 2026 PMID 42751285
Written from 25 PubMed abstracts, each one listed by PMID above. Published: 2026-06-14. Last written: 2026-09-02 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.